| Cancer (3241) |  |
| Leukemia (66) | |
| Neoplasms and tumors (1662) | |
| Cancer (3241) | |
| Leukemia (66) | |
| Neoplasms and tumors (1662) | |
when researchers from the University of Iowa conducted a literature review they found that PTEN mutations show up in 40 percent of breast cancer cases up to 70 percent of prostate cancer cases and nearly half of all leukemia cases.
Leukemia patients have been treated successfully using HSC transplants but medical experts believe blood stem cells have the potential to be used more widely.
The team found that there were also cases of other cancer types in families with these hereditary mutations such as leukemia
including leukemia, lymphoma, and bladder, breast, lung, and ovarian tumors. Staggering these drugs proved particularly powerful against a type of breast cancer cell known as triple-negative,
It's shown a broad killing effect for a variety of cancer cell lines including leukemia breast
#Uncovering Genetic Factors in Leukemia Northwestern Medicine scientists have discovered how a gene linked to leukemia functions,
making that chromosome an important avenue for researching the genetic basis of the cancer. major goal of my laboratory is to identify the specific gene or genes on chromosome 21 responsible for the increased incidence of leukemia in this population,
In previous work, Crispino and colleagues found that a gene on chromosome 21 called DYRK1A contributes to the development of leukemia.
because human B-cell acute lymphoblastic leukemia cases show increased levels of DYRK1A, said Crispino. he results suggest that DYRK1A may be a novel target for therapy in this form of leukemia.
This work was supported by a National institutes of health grant, the Samuel Waxman Cancer Research Foundation, the Leukemia and Lymphoma Society, the Rally Foundation and the Bear Necessities Foundation e
#Researchers Find New Clue to Halting Leukemia Relapse A protein domain once considered of little importance may be key to helping patients who are fighting acute myeloid leukemia (AML) avoid a relapse.
who is also part of the leukemia and lymphoma teams at Texas Children Hospital. Ball said STAT3 has been a target for scientists trying to shut down cancer cells.
#New Leukemia Gene Stops Blood cells rowing Upuniversity of Manchester scientists have identified a gene FOXC1 that,
About 60 percent of children and adults with T-cell leukemia harbor a Notch mutation. But drugs designed to block Notch have caused serious side effects such as severe diarrhea or skin cancers.
While the majority of kids with T-cell leukemia are cured, about 20 percent will relapse. Those kids face a grim prognosis.
#Study charts'genomic biography'of form of leukemia A new study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard offers a glimpse of the wealth of information
that can be gleaned by combing the genome of a large collection of leukemia tissue samples. By analyzing genetic material in chronic lymphocytic leukemia (CLL) and normal tissue from more than 500 patients,
New Option to Diagnose Leukemia Iranian researchers from Tarbiat Modarres University designed a biosensor that enables the early diagnosis of leukemia in the test sample by using naked eyes.
The aim of the research was to design an effective system to diagnose blood cancer (leukemia) by using gold nanobars.
and it may result in leukemia. Diagnosis tests are very time-consuming, expensive and difficult in some cases.
like leukemia, or those where Ash1l might be expressed highly or mutated.""It's vital to understand how the basic,
"Leukemia is a cancer of the body's blood-forming tissues, so it's an obvious place that we plan to look at next.
Dysfunction of blood-forming stem cells is well known in illnesses like leukemia and bone marrow failure disorders.
The Ash1l (Absent, small or homeotic 1-like) gene is part of a family of genes that includes MLL1 (Mixed Lineage Leukemia 1),
a gene that is frequently mutated in patients who develop leukemia. The research found that both genes contribute to blood renewal;
The comparison involved the normal and tumor genomes from 43 children and adults with brain tumors, leukemia, melanoma and the pediatric eye tumor retinoblastoma."
"Using CONSERTING, researchers discovered genetic alterations driving pediatric leukemia, the pediatric brain tumor low-grade glioma, the adult brain tumor glioblastoma and retinoblastoma.
#New leukemia gene stops blood cells'growing up'Scientists have identified a gene--FOXC1--that, if switched on, causes more aggressive cancer in a fifth of acute myeloid leukemia (AML) patients,
it causes more aggressive forms of leukemia.""Nell Barrie, senior science communication manager at Cancer Research UK, said:"
'Complex array of mutations found in rare, aggressive leukemia Sezary syndrome (SS), an aggressive leukemia of mature T cells, is complicated more at a molecular level than ever suspected, according to investigators from the Perelman School of medicine at the University of Pennsylvania.
With a poor prognosis and limited options for targeted therapies, fighting SS needs new treatment approaches.
has identified an inhibitor of the Pin1 enzyme that can address both these challenges in acute promyelocytic leukemia (APL) and triple-negative breast cancer.
in order to bind Pin1. hile it has been shown previously that ATRA ability to degrade the leukemia-causing fusion oncogene PML-RAR causes ATRA to stop the leukemia stem cells that drive APL,
Dangers of CAR T cell Therapy CAR-equipped T cells have proven to be remarkably successful in the treatment of various forms of chemotherapy-resistant leukemia
when leukemia cells were implanted into mice. These cancer cells were powerfully and selectively eliminated by the Lim group new CAR T cells,
While successful against blood cancers such as leukemia, CAR T cells have shown so far less efficacy against solid tumors that effect the colon, breast, prostrate, brain and other tissues.
along with David Porter MD the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center.
which is designed to bind to a protein called CD19 found on the surface of B cells including the cancerous B cells that characterize several types of leukemia.
whose cancers returned as CD19-negative leukemia that would not have been targeted by the modified cells.
Surprisingly the loss of STAT3 in NK cells of the mouse led not to a decrease but to an increase in killing activity against melanoma cells and leukemia cells.
and some suffered leukemia-like diseases as a side effect (see he Glimmering Promise of Gene therapy.
and developmental disorders, including some forms of leukemia and inherited heart problems. Until now, Hetzer said,
The approach has been used to treat leukemia as well as lymphoma, according to Dr. Rapoport, who is the Director of the Blood and Marrow Transplant Program at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.
News and information June 29th, 2015efforts to Use Smart Nanocarriers to Cure Leukemia Yield Promising Results June 29th, 2015making new materials with micro-explosions:
A novel microscope for nanosystems June 25th, 2015iranian Researchers Synthesize Nanostructures with Controlled Shape, Structure June 25th, 2015discoveries June 29th, 2015efforts to Use Smart Nanocarriers to Cure Leukemia Yield
New technique combines electron microscopy and synchrotron X-rays to track chemical reactions under real operating conditions June 29th, 2015announcements June 29th, 2015efforts to Use Smart Nanocarriers to Cure Leukemia Yield Promising
which might give an impact on tyrosine kinase-targeted leukemia therapy, was found to be expressed in a leukemia cell line.
The function of the lncrna CCDC26 is understood not fully; however, researchers at Hiroshima University revealed the mechanisms by
The results provide new insights into leukemia recurrence and may help to develop new leukemia therapies.
Recent transcriptomic studies have revealed the existence of numerous RNAS that are relatively long but not translated into proteins.
Leukemia cells in which CCDC26 was knocked down showed enhanced survival periods after serum withdrawal. A KIT-specific inhibitor reversed this increased survival of the cells.
Leukemia characterized by a mutated copy number of CCDC26 might be treated by KIT-targeted therapy"quoted Dr. Hirano o
#Disrupting tumor cell'microenvironment'suggests a new way to treat a prevalent childhood leukemia Researchers at NYU Langone Medical center
and its Laura and Isaac Perlmutter Cancer Center are reporting a potentially important discovery in the battle against one of the most devastating forms of leukemia that accounts for as many as one in five children with a particularly aggressive form of the disease
""Our experiments showed that blocking CXCR4 decimated leukemia cells, "says co-senior study investigator and NYU Langone cell biologist Susan Schwab, Phd.
and disrupting leukemia cells'microenvironment--or what goes on around them--could prove effective against the disease."
and an early career scientist at the Howard Hughes Medical Institute, says experiments in his laboratory had shown that leukemia-initiating cells concentrate in the bone marrow near CXCL12-producing blood vessels.
#Scientists decipher the molecular basis of an as yet incurable leukemia in children Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children.
differing by specific changes in the genetic material of the leukemia cells, but also by their response to therapies.
and Zurich has succeeded in decoding the molecular characteristics of an as yet incurable subtype of leukemia,
resulting in the formation of a new oncogenic protein encoded by parts of the genes TCF3 and HLF, respectively (TCF3-HLF-positive leukemia cells).
early success treating leukemia and lymphoma patients with a first generation of experimental T cell therapies developed by its academic partners.
although Brentjens cautions not to expect the same results that CAR-T cells have shown so far in leukemia and lymphomaemission rates well above 50 percent.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011